TABLE 1.

Summary of TAF, TFV, and TFV-DP concentrations from the mouse (TAF release rate 0.23 ± 0.07 mg d⁻¹) and sheep (TAF release rate 0.30 ± 0.04 mg d⁻¹) studies at equilibrium.

Animal, analyte, matrix a	n	% above LLOQ b	Median (IQR c )
Mouse, TAF, plasma	9	100
ng mL−1			13.2 (9.6–14.3)
Mouse, TFV, plasma	9	100
ng mL−1			215.7 (198.3–275.2)
Mouse, TFV, dermal tissue	6	100
ng mg−1			122.0 (97.1–182.6)
fmol mg−1			425 × 103 (338 × 103–636 × 103)
Mouse, TFV-DP, dermal tissue	6	100
fmol mg−1			1,419 (750.1–2,561)
Sheep, TAF, plasma d	8	100	0.28 (0.21–0.47)
ng mL−1
Sheep, TFV, plasma d	5	63	1.48 (1.28–1.96)
ng mL−1
Sheep, TFV, dermal tissue	3	75
ng mg−1			7.21
fmol mg−1			425 × 103
Sheep, TFV-DP, dermal tissue	3	75
fmol mg−1			706.2

TFV, tenofovir; TAF, tenofovir alafenamide.

^aAll values correspond to time points with the implant in place.

^bProportion of samples that contained quantifiable drug concentrations.

^cInterquartile range, between first (25th percentile) and third (75th percentile) quartiles.

^dStudy days 7–14.